+ All Categories
Home > Documents > Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... ·...

Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... ·...

Date post: 07-Aug-2020
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
28
Fourth Quarter & Full Year 2019 Financial Results Conference Call March 5, 2020
Transcript
Page 1: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

Fourth Quarter & Full Year 2019Financial Results Conference Call

March 5, 2020

Page 2: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

2

This Presentation has been prepared by Calumet Specialty Products Partners, L.P. (the “Company,” “Calumet,” "we," "our," or like terms)as of March 5, 2020. The information in this Presentation includes certain “forward-looking statements.” These statements can be

identified by the use of forward-looking terminology including “may,” “intend,” “believe,” “expect,” “anticipate,” “estimate,” “forecast,”“continue” or other similar words. The statements discussed in this Presentation that are not purely historical data are forward-lookingstatements. These forward-looking statements discuss future expectations or state other “forward-looking” information and involve risksand uncertainties. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary

statements included in our most recent Annual Report on Form 10-K and Current Reports on Form 8-K. The risk factors and other factorsnoted in our most recent Annual Report on Form 10-K and Current Reports on Form 8-K could cause our actual results to differ materiallyfrom those contained in any forward-looking statement.

Our forward-looking statements are not guarantees of future performance, and actual results and future performance may differ materiallyfrom those suggested in any forward-looking statement. All subsequent written and oral forward-looking statements attributable to us or topersons acting on our behalf are expressly qualified in their entirety by the foregoing. Existing and prospective investors are cautioned notto place undue reliance on such forward-looking statements, which speak only as of the date of this Presentation. We undertake no

obligation to publicly release the results of any revisions to any such forward-looking statements that may be made to reflect events orcircumstances after the date of this Presentation or to reflect the occurrence of unanticipated events.

Non-GAAP Financial Measures

Adjusted EBITDA, Pro forma Adjusted EBITDA, Adjusted EBITDA (ex-LCM/LIFO), Adjusted EBITDA margin, Adjusted EBITDA (ex-

LCM/LIFO) margin, Gross profit per barrel (ex-LCM/LIFO), Adjusted net income, and leverage ratio are non-GAAP financial measures

provided in this Presentation. Reconciliations to the most comparable GAAP financial measures are included in the Appendix to this

Presentation. These non-GAAP financial measures are not defined by GAAP and should not be considered in isolation or as an

alternative to net income (loss) or other financial measures prepared in accordance with GAAP. We do not provide reconciliation of non-

GAAP financial measures on a forward-looking basis as it is impractical to do so without unreasonable effort.

Forward Looking Statements

Page 3: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

3

$262.8 MM of Adjusted EBITDA(2)

✓ Specialty Adj. EBITDA(2) of $207.9 MM; up 24% Y/Y

✓ Fuels Adj. EBITDA(2) of $152.5 MM

✓ Strong Cash Flow from Operations of $191.9 MM

2019 Fourth Quarter & Full Year Highlights(1)

3

Fourth Quarter 2019

$49.9 MM Adjusted EBITDA(2)

✓ Specialty Adj. EBITDA(2) of $42.8 MM

✓ Fuels Adj. EBITDA(2) of $28.7 MM

✓ Performed well through Shreveport turnaround

Strategy & Balance Sheet

✓ Divested San Antonio refinery

✓ Refinanced 2021 notes in unsecured market

✓ Revenue growth in specialty waxes business

Full Year 2019

Strategy & Balance Sheet

✓ Leverage down to 4.0x (4.6x ex-LCM/LIFO)

✓ Reduced debt $391 MM & interest $21 MM Y/Y

✓ Upgraded by Moody’s, S&P and Fitch

Specialty Margin Growth

✓ Specialty sales volume growth of 4%

✓ Gross profit/bbl(2) of $34.41 vs. $32.11 Y/Y

✓ Adj. EBITDA(2) margin of 15.4% vs.12.2% Y/Y

Specialty Margin Growth

✓ Adj. EBITDA(2) margin of 14.2% up 50 bps Y/Y

✓ Rationalized 2,100 bpd of low-margin volume

✓ Backfilling capacity with higher-margin production

(1) This presentation reflects the addition of our Corporate segment, which was added in the third quarter of 2019

(2) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations

Page 4: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

4

Strategic Priorities

▪ Pivoting from turnaround story to growth

– Strengthening our commercial excellence capabilities

– Debottlenecking continues to drive utilization and yield improvements

– Product rationalization driving margin expansion

– Self-Help program now part of culture

▪ Further deleveraging remains a top priority

– Consistently generating cash flow from operations

– Expect to address the 2022 and/or 2023 maturities in the near-term

▪ Focused on the core

– Targeting gross profit per barrel over $40 and Adj. EBITDA margins over 15% annually

– Acquired Paralogics, LLC; selectively evaluating further bolt-on acquisitions

– Reviewing strategic options for the Great Falls refinery

Page 5: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

5

M&A

Opportunistic Growth

Projects

Operations Excellence

Self-Help Delivery

• Inventories(2) reduced $16 MM Y/Y

• Debottleneck completed at

Shreveport & Finished Lubricants

facilitiesStrong Utilization• Record(1) Fuels sales

• Record Great Falls throughput

• Record Cotton Valley crude runs

• Record TruFuel sales

• Record Dickinson throughput

Strong Cash Flows• Highest Free Cash Flow(3)

since 2012

• Highest Cash Flow from

Operations since 2015

Better Cost Management

• Transportation costs down $14 MM Y/Y

• Interest expense down $21 MM Y/Y

Record Safety Performance

• Best performance for personal safety

• Best performance for process safety

Executing Operations Excellence

(1) Pro forma for divestments of Dakota Prairie and Superior refineries

(2) As stated in the Statement of Cash Flows

(3) Cash Flow from Operating Activities less Additions to property, plant and equipment Roadmap for Growth

Page 6: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

6

$3,452.6 $3,497.5

$262.8

$300.8

0

50

100

150

200

250

300

350

400

450

500

$0.0

$500.0

$1,000.0

$1,500.0

$2,000.0

$2,500.0

$3,000.0

$3,500.0

$4,000.0

Revenue Adj. EBITDA(1)

$774.8

$848.0

$49.9

$105.0(2)

0

50

100

150

200

250

$0.0

$100.0

$200.0

$300.0

$400.0

$500.0

$600.0

$700.0

$800.0

$900.0

Revenue Adj. EBITDA(1)

Consolidated 4Q and FY19 Financial Results ($MM)

4Q184Q19

Fourth Quarter Full Year

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Adjusted to remove $2.0 million from the divestiture of Anchor Drilling Fluids USA, LLC

FY18FY19

Page 7: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

7

Adjusted EBITDA(1) Bridge – FY19 vs. FY18 ($MM)

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Includes hedging

(3) Includes plant operating and maintenance costs including RINs activities

(4) Includes reduced transportation costs, offset by 2017 Superior RINs exemption received in 2018

$300.8

($79.8)

$11.7

$37.7

$19.0

($17.9) ($2.5)($6.2)

$262.8

FY18 Adj. EBITDA (1) Fuels Margin (2) Specialty Margin (2) Fuels Volume Specialty Volume Operating Costs (3) Other (4) SG&A FY19 Adj. EBITDA (1)

Page 8: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

8

Specialty Products Segment Highlights

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations.

▪ Adj. EBITDA(1):

– 4Q: Strong Finished Lubricants performance, offset by Shreveport turnaround activity

– FY: Reflects solid growth in Solvents, Naphthenic Oils & Finished Lubricants

▪ Adj. EBITDA(1) Margin :

– 4Q: Improved sales mix from rationalizing 2,100 bpd of lower margin SKUs

– FY: Improved sales volumes and product mix

▪ Gross Profit/ bbl(1)

– 4Q: Impacted by significantly tighter crude differentials

– FY: Improved sales volumes and product mix

Adj. EBITDA(1) Adj. EBITDA Margin(1) Gross Profit/ bbl(1)

$MM Y/Y ∆ % Y/Y ∆ $/bbl Y/Y ∆

4Q19 $ 42.8 (5.3)% 14.2% +50bps $ 30.94 (3.3)%

FY19 $ 207.9 23.5% 15.4% +320bps $ 34.41 7.2%

Page 9: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

9

Improved Specialty Performance FY19 vs. FY18 ($MM)

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Includes hedging

(3) Includes costs related to transportation, and other expenses

$166.3 $168.3

$11.7

$19.0 $2.2 $8.1

($1.4)$207.9

FY18 Adj. EBITDA (AsPreviously Reported) (1)

FY18 Adj. EBITDA (1) Specialty Margin (2) Specialty Volume Operating Costs Other (3) SG&A FY19 Adj. EBITDA (1)

Page 10: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

10

Fuel Products Segment Highlights

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations.

(2) Production volume is as reported and not pro-forma for the sale of the San Antonio refinery

▪ Adj. EBITDA(1):

– 4Q: Avg. WCS and Midland differentials tightened $(15.50) and $(6.61), respectively

– FY: Avg. WCS and Midland differentials tightened $(13.29) and $(6.28), respectively

▪ Production Volume(2):

– 4Q: Impacted by Shreveport turnaround and San Antonio divestment

– FY: Improved throughput and record capacity utilization across portfolio

▪ Gross Profit/ bbl(1):

– Both 4Q and FY declined as WCS/WTI differential tightened meaningfully

Adj. EBITDA(1) Production Volume(2) Gross Profit/ bbl(1)

$MM Y/Y ∆ Kbd Y/Y ∆ $/bbl Y/Y ∆

4Q19 $ 28.7 (65.4)% 68.5 (1.9)% $ 3.50 (71.4)%

FY19 $ 152.5 (33.7)% 76.4 8.8% $ 3.34 (53.7)%

– WCS/WTI avg. differential ($19.16) vs. ($34.67) in 4Q18

– WCS/WTI avg differential ($13.56) vs. ($26.85) in FY18

– Midland/WTI avg. differential $0.93 vs. ($5.68) in 4Q18

– Midland/WTI avg. differential ($0.72) vs. ($7.00) in FY18

Page 11: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

11

Strong Fuels Performance FY19 vs. FY18 Despite Headwinds ($MM)

(1) Excludes non-cash LCM/LIFO adjustments See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Includes hedging

(3) Includes plant operating and maintenance costs including RINs activities

(4) Includes reduced transportation costs, offset by 2017 Superior RINs exemption received in 2018

$134.5

$230.0

($79.8)

$37.7

($20.1)

($17.0)

$1.7

$152.5

FY18 Adj. EBITDA (AsPreviously Reported) (1)

FY18 Adj. EBITDA (1) Fuels Margin (2) Fuels Volume Operating Costs (3) Other (4) SG&A FY19 Adj. EBITDA (1)

Page 12: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

12

FY19 Sources & Uses of Cash ($MM)

(1) Does not include Turnaround Costs

(2) Includes $4.0 million of legal fees and pipeline settlements

(3) Cash flow from financing activities

(4) Additions to Property, Plant and Equipment including Turnaround Costs

$155.7

$209.7

$55.1 $14.3

($343.0)

($72.7) $19.1

FY18 Cash Balance Cash Flow fromOperations (1)

Net Proceeds from theSale of San Antonio

(2)

Other Investing Reduction of Debt (3) Capex (4) FY19 Cash Balance

Page 13: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

13

Continuously Improving Credit Metrics

(1) See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Fixed Charge Coverage Ratio defined as Adj. EBITDA divided by consolidated interest expense (plus capitalized interest), neither of which has been pro-forma adjusted for acquisitions or refinancing activity

(3) Excludes $350 million of restricted cash

(2)

(3)

▪ Credit metrics improved Y/Y

― Net Debt/TTM Adj. EBITDA(1) by 1.6x

― Fixed Charge Coverage(2) by 0.6x

▪ Liquidity down Y/Y due to debt repayment

(1)

Page 14: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

14

Calumet Focused on Specialty Growth

Scott Obermeier: Executive Vice President – Commercial

▪ Appointed Executive Vice President Commercial effective January 2020

- Responsible for Lubricating Oils, Solvents and Waxes

- Corporate Marketing, R&D and Customer Service

▪ Calumet’s General Manager of Base Oils since mid-2018 and Vice

President of Commercial Excellence since late 2017

▪ Previously Vice President of Univar’s organic chemicals business

▪ 20+ years experience in specialty chemicals

Page 15: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

Acquired Paralogics, LLC

15

Specialty wax production

Import value chain logistics

Blending and Formulating

Fully integrated wax

solutionsSpecialty wax

production

Blending &

Formulating

Packaging &

Distribution

Fully integrated wax

solutions

[---------------------------------------------------- Wax Business Value Chain ------------------------------------------------------]

▪ Paralogics, LLC will add:

― 20 MM pounds wax blending capacity

― Formulating and blending expertise

― Packaging & distribution capability

▪ Current Calumet wax business

― 100 MM pounds per year production

― $119 MM 2019 revenues

▪ Investment Logic:

― Penetrate higher margin end markets

― Value chain extension into packaging and blends

― Additional technical expertise in high margin formulations

― Synergies with Calumet wax business

― Adds additional logistics hub

Page 16: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

16

Self-Help in Action: $40MM Adj. EBITDA Goal in 2020

[-------- Specialty Focused -------]

Cost Reductions

Raw Material Optimization

Margin Enhancements

Facilitated Non-Core Asset Sales

Specialty Growth Initiatives

Two Debottlenecking Projects

Further Rationalizing Low Margin Products

Additional Finished Lubricant Expansion

Cost Reduction Plan(1)

Reducing Professional Services

Facility Fixed Costs

Corporate Staffing

2020 Goal: $40 MM

Adj. EBITDA

(1) Anticipate approximately $10 million in one-time costs to implement

2021

Self-Help Phase II(2019-2021)

On track for $100 MM Adj.

EBITDA Goal

2019: $30 MM 2020 2021

Self-Help Phase I(2016-2018)

Delivered $182 MM

Adj. EBITDA

Page 17: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

17

FY20 Outlook

Specialty Products

▪ Continue expanding Adj. EBITDA margin

▪ Gross profit per barrel over $40

▪ Specialty commercial initiatives to drive growth

Fuel Products

▪ Improved WCS crude margins

▪ Initiatives in place to capture local rack differentials

Corporate/Strategic

▪ Integrate Paralogics, LLC

▪ Review strategic options for Great Falls refinery

▪ Self-Help Phase II initiatives expected to deliver $40 million of incremental Adj. EBITDA

– Specialty growth and product rationalization ~ $20 million

– SG&A costs $20 million lower Y/Y

▪ Capex guidance of $80-$90 million

Page 18: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

18

AppendixSupplemental Financial Data

Page 19: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

19

Our Strategy & Roadmap for Growth

▪ Focus portfolio on high-return,

niche specialty markets where

we are competitively advantaged

▪ Capture one-to-two-year

payouts with low capital

investment requirements

▪ Reduce costs, optimize

raw materials and

enhance margins

Strategic

M&A

Opportunistic Growth

Projects

Operations Excellence

Page 20: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

20

Adjusted EBITDA(1) Bridge – 4Q19 vs. 4Q18 ($MM)

$105.0

($76.2)($3.3)

$0.4

($5.5)

$12.8

$11.1

$5.6

$49.9

4Q18 Adj. EBITDA(1)(2)

Fuels Margin (3) Specialty Margin (3) Fuels Volume Specialty Volume Operating Costs (4) Other (5) SG&A 4Q19 Adj. EBITDA (1)

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Adjusted to remove $2.0 million from the divestiture of Anchor Drilling Fluids USA, LLC

(3) Includes hedging

(4) Includes plant operating and maintenance costs including RINs activities

(5) Includes costs related to transportation

Page 21: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

21

Specialty Adjusted EBITDA(1) Bridge – 4Q19 vs. 4Q18 ($MM)

$44.1 $45.2 ($3.3)

($5.5)

$0.1

$4.3 $2.0

$42.8

4Q18 Adj. EBITDA (AsPreviously Reported)(1)

4Q18 Adj. EBITDA (1) Specialty Margin (2) Specialty Volume Operating Costs Other (3) SG&A 4Q19 Adj. EBITDA (1)

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations(2) Includes hedging

(3) Includes costs related to transportation

Page 22: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

22

Fuels Adjusted EBITDA(1) Bridge – 4Q19 vs. 4Q18 ($MM)

$60.9

$82.9

($76.2)

$0.4

$12.7 $3.8

$5.1

$28.7

4Q18 Adj. EBITDA (AsPreviously Reported) (1)

4Q18 Adj. EBITDA (1) Fuels Margin (2) Fuels Volume Operating Costs (3) Other (4) SG&A 4Q19 Adj. EBITDA (1)

(1) Excludes non-cash LCM/LIFO adjustments. See Appendix to this presentation for GAAP to Non-GAAP reconciliations

(2) Includes hedging

(3) Includes plant operating and maintenance costs including RINs activities

(4) Includes costs related to transportation

Page 23: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

23

Exhibit A: Capital Structure OverviewActual Actual Actual Actual Actual Actual Actual Actual

($ in millions) 3/31/18 6/30/18 09/30/18 12/31/18 03/31/19 06/30/19 09/30/19 12/31/19

Cash $ 496.6 $ 38.8 $ 65.5 $ 155.7 $ 152.9 $ 173.5 $ 164.2 $ 19.1

ABL Revolver Borrowings $ — $ 0.1 $ 0.1 $ — $ — $ — $ — $ —

7.625% Senior Notes due 2022 350.0 350.0 350.0 350.0 350.0 350.0 350.0 350.0

6.50% Senior Notes due 2021 900.0 900.0 900.0 900.0 876.8 810.2 761.2 —

7.75% Senior Notes due 2023 325.0 325.0 325.0 325.0 325.0 325.0 325.0 325.0

11.00% Senior Notes due 2025 — — — — — — — 550.0

11.50% Senior Secured Notes due 2021 400.0 — — — — — — —

Finance Leases 43.7 42.2 41.8 42.4 3.3 3.0 2.8 2.7

Other 6.3 5.9 5.5 5.2 4.9 4.5 4.1 3.8

Total Debt $ 2,025.0 $ 1,623.2 $ 1,622.4 $ 1,622.6 $ 1,560.0 $ 1,492.7 $ 1,443.1 $ 1,231.5

Partners’ Capital $ 115.4 $ 66.6 $ 51.2 $ 65.7 $ 83.5 $ 67.1 $ 62.8 $ 21.6

Total Capitalization $ 2,140.4 $ 1,689.8 $ 1,673.6 $ 1,688.3 $ 1,643.5 $ 1,559.8 $ 1,505.9 $ 1,253.1

LTM Adjusted EBITDA (as reported) $ 313.5 $ 290.8 $ 249.4 $ 263.9 $ 286.6 $ 287.3 $ 306.5 $ 304.6

Net Debt / LTM Adjusted EBITDA (as reported) 4.9x 5.4x 6.2x 5.6x 4.9x 4.6x 4.2x 4.0x

Page 24: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

24

EXHIBIT B: Reconciliation of Adjusted EBITDA to Net Income (Loss)

(1) In 2018, the Company and The Heritage Group formed Biosyn Holdings, LLC (“Biosyn”) for the purposes of acquiring Biosynthetic Technologies, LLC (“Biosynthetic Technologies”), a startup companywhich developed an intellectual property portfolio for the manufacture of renewable-based and biodegradable esters. The initial cash investment of $3.8 million made by the Company into Biosyn wasexpensed in the period ended March 31, 2018 given Biosyn’s operations were all related to research and development. The Company accounts for its ownership in Biosyn under the equity method ofaccounting. During March 2019, the Company sold its investment to The Heritage Group and recognized a gain of $5.0 million. For comparability purposes, $3.8 million of the gain is included in AdjustedEBITDA for the three months ended March 31, 2019.

($ in millions) 3/31/18 06/30/18 09/30/18 12/31/18 03/31/19 06/30/19 09/30/19 12/31/19

Segment Adjusted EBITDA

Corporate Adjusted EBITDA $ (29.6) $ (20.8) $ (24.0) $ (23.1) $ (24.8) $ (28.4) $ (22.8) $ (21.6)

Specialty products Adjusted EBITDA 39.4 53.3 36.6 32.9 64.2 54.9 52.2 48.9

Fuel products Adjusted EBITDA 66.6 46.8 41.9 43.9 58.3 53.1 44.1 26.5

Discontinued operations Adjusted EBITDA (1.4) (0.4) (0.2) 2.0 — — — —

Adjusted EBITDA $ 75.0 $ 78.9 $ 54.3 $ 55.7 $ 97.7 $ 79.6 $ 73.5 $ 53.8

Less:

Unrealized (gain) loss on derivative Instruments

$ (2.0) $ (0.8) $ 2.4 $ (29.8) $ 2.6 $ 12.2 $ 5.4 $ 5.9

Realized (gain) loss derivative activities, not included in net income (loss) or settled in a prior period

— 2.1 0.7 (2.8) — — — —

Amortization of turnaround costs 3.3 2.7 2.7 4.1 4.8 5.6 6.1 2.8

Debt extinguishment costs 0.6 58.2 — — (0.4) (0.3) — 2.9

(Gain) loss on the sale of business, net 1.6 (1.8) (3.4) 2.9 — — — 8.7

Loss on impairment and disposal of assets 0.5 0.7 0.9 3.2 11.7 16.2 3.2 5.9

Other non-recurring expenses — — — — — — 1.3 2.2

Gain on sale of unconsolidated affiliate (1) — — — — (1.2) — — —

Equity based compensation and other items 1.1 1.9 (0.2) (4.1) 3.4 2.3 0.4 1.3

EBITDA $ 69.9 $ 15.9 $ 51.2 $ 82.2 $ 76.8 $ 43.6 $ 57.1 $ 24.1

Less:

Interest expense $ 45.2 $ 37.5 $ 37.7 $ 35.1 $ 32.3 $ 33.1 $ 33.8 $ 35.4

Depreciation and amortization 29.7 29.5 29.6 29.3 28.2 27.0 27.4 27.5

Income tax expense (benefit) (0.2) 0.8 0.4 (0.3) (0.1) 0.3 0.5 (0.2)

Net income (loss) $ (4.8) $ (51.9) $ (16.5) $ 18.1 $ 16.4 $ (16.8) $ (4.6) $ (36.6)

Page 25: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

25

EXHIBIT C: Reconciliation of Net Income (Loss) to Adj. EBITDA & Pro Forma Adj. EBITDA (ex-LCM/LIFO)

(1) In 2018, the Company and The Heritage Group formed Biosyn for the purposes of acquiring Biosynthetic Technologies, a startup company which developed an intellectual property portfolio for themanufacture of renewable-based and biodegradable esters. The initial cash investment of $3.8 million made by the Company into Biosyn was expensed in the period ended March 31, 2018 given Biosyn’soperations were all related to research and development. The Company accounts for its ownership in Biosyn under the equity method of accounting. During March 2019, the Company sold its investment toThe Heritage Group and recognized a gain of $5.0 million. For comparability purposes, $3.8 million of the gain is included in Adjusted EBITDA for the three months ended March 31, 2019.

(2) Pro forma adjusts for divestitures of the Superior Refinery and Anchor Drilling Fluids USA, LLC in 4Q17

($ in millions) 12/31/17 3/31/18 06/30/18 09/30/18 12/31/18 03/31/19 06/30/19 09/30/19 12/31/19

Net income (loss) $ (83.6) $ (4.8) $ (51.9) $ (16.5) $ 18.1 $ 16.4 $ (16.8) $ (4.6) $ (38.6)

Add:

Interest expense $ 47.3 $ 45.2 $ 37.5 $ 37.7 $ 35.1 $ 32.3 $ 33.1 $ 33.8 $ 35.4

Depreciation and amortization 37.9 29.7 29.5 29.6 29.3 28.2 27.0 27.4 27.5

Income tax expense (benefit) — (0.2) 0.8 0.4 (0.3) (0.1) 0.3 0.5 (0.2)

EBITDA $ 1.6 $ 69.9 $ 15.9 $ 51.2 $ 82.2 $ 76.8 $ 43.6 $ 57.1 $ 24.1

Add:

Unrealized (gain) loss on derivative Instruments

$ (1.4) $ (2.0) $ (0.8) $ 2.4 $ (29.8) $ 2.6 $ 12.2 $ 5.4 $ 5.9

Realized (gain) loss derivative activities, not included in net income (loss) or settled in a prior period

— — 2.1 0.7 (2.8) — — — —

Amortization of turnaround costs 3.9 3.3 2.7 2.7 4.1 4.8 5.6 6.1 2.8

Debt extinguishment costs — 0.6 58.2 — — (0.4) (0.3) — 2.9

(Gain) loss on sale of business, net (173.4) 1.6 (1.8) (3.4) 2.9 — — — 8.7

Loss on impairment and disposal of assets 0.2 0.5 0.7 0.9 3.2 11.7 16.2 3.2 5.9

Other non-recurring expenses 206.9 — — — — — — 1.3 2.2

Gain on sale of unconsolidated affiliate (1) — — — — — (1.2) — — —

Equity based compensation and other items 3.4 1.1 1.9 (0.2) (4.1) 3.4 2.3 0.4 1.3

Adjusted ABITDA $ 41.2 $ 75.0 $ 78.9 $ 54.3 $ 55.7 $ 97.7 $ 79.6 $ 73.5 $ 53.8

Less:

Discontinued operations Adjusted EBITDA (0.3) (1.4) (0.4) (0.2) 2.0 — — — —

Superior Adjusted EBITDA 16.8 — — — — — — —

Total pro forma Adjusted EBITDA (2) 24.7 76.4 79.3 54.5 53.7 97.7 79.6 73.5 53.8

LCM inventory adjustments (14.1) (3.1) (14.0) 2.3 45.4 (38.9) (2.6) 2.7 3.0

LIFO inventory layer adjustments 2.9 — — 0.4 5.9 0.9 — — (6.9)

Less: Superior LIFO/LCM 0.5 — — — — — — — —

Pro forma EBITDA (excluding LCM/LIFO) (2) 14.0 73.3 65.3 57.2 105.0 59.7 77.0 76.2 49.9

Adjusted EBITDA (excluding LCM/LIFO) 30.0 71.9 64.9 57.0 107.0 59.7 77.0 76.2 49.9

Page 26: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

26

EXHIBIT D: Reconciliation of Operating Metrics (ex-LCM/LIFO)Three Months Ended December 31, Year Ended December 31,

($ in millions, except per barrel data) 2019 2018 2019 2018

Specialty Adjusted EBITDA $ 48.9 $ 32.9 $ 220.2 $ 162.2

LCM inventory adjustments (2.4) 9.7 (9.5) 3.4

LIFO inventory layer adjustments (3.7) 2.6 (2.8) 2.7

Specialty Adjusted EBITDA (ex-LCM/LIFO) $ 42.8 $ 45.2 $ 207.9 $ 168.3

Fuel Adjusted EBITDA $ 26.5 $ 43.9 $ 182.0 $ 199.2

LCM inventory adjustments 5.4 35.7 (26.3) 27.2

LIFO inventory layer adjustments (3.2) 3.3 (3.2) 3.6

Fuel Adjusted EBITDA (ex-LCM/LIFO) $ 28.7 $ 82.9 $ 152.5 $ 230.0

Corporate Adjusted EBITDA $ (21.6) $ (23.1) $ (97.6) $ (97.5)

Total Adjusted EBITDA $ 53.8 $ 55.7 $ 304.6 $ 263.9

LCM inventory adjustments 3.0 45.4 (35.8) 30.6

LIFO inventory layer adjustments (6.9) 5.9 (6.0) 6.3

Total Adjusted EBITDA (ex-LCM/LIFO) $ 49.9 $ 107.0 $ 262.8 $ 300.8

Reported Specialty gross profit per barrel $ 33.82 $ 26.57 $ 35.74 $ 31.41

LCM/LIFO inventory adjustments per barrel (2.88) 5.43 (1.33) 0.70

Specialty gross profit per barrel (ex-LCM/LIFO) $ 30.94 $ 32.00 $ 34.41 $ 32.11

Reported Fuel gross profit per barrel $ 3.18 $ 6.80 $ 4.35 $ 6.07

LCM/LIFO inventory adjustments per barrel 0.32 5.44 (1.01) 1.15

Fuel gross profit per barrel (ex-LCM/LIFO) $ 3.50 $ 12.24 $ 3.34 $ 7.22

Page 27: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

27

EXHIBIT E: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

(1) Beginning in third quarter 2019, Amortization of turnaround costs were no longer included in the calculation

Three Months Ended December 31,

Year Ended December 31,

($ in millions, except per unit data) 2019 2018 2019 2018

Net income (loss) $ (38.6) $ 18.1 $ (43.6) $ (55.1)

LCM 3.0 45.4 (35.8) 30.6

LIFO (6.9) 5.9 (6.0) 6.3

Unrealized (gain) loss on derivative instruments 5.9 (29.8) 26.1 (30.2)

Realized gain on derivatives, not included in net income (loss) or settled in a prior period — — — —

Debt extinguishment costs 2.9 — 2.2 58.8

Loss on impairment and disposal of assets 5.9 — 37.0 —

Gain on sale of unconsolidated affiliate — — (1.2) —

(Gain) loss on sale of business, net 8.7 2.9 8.7 (0.7)

Amortization of turnaround costs (1) — — — —

Equity based compensation and other non-cash items 1.3 (3.7) 7.4 4.0

Adjusted net income (loss) $ (17.8) $ 38.8 $ (5.2) $ 13.7

Adjusted net income (loss) per unit $ (0.23) $ 0.50 $ (0.07) $ 0.18

Average limited partner units - diluted 78,332,671 78,218,831 78,212,136 77,943,992

Page 28: Fourth Quarter & Full Year 2019calumetspecialty.investorroom.com/download/Q4+2019+EPS... · 2020-03-05 · Refinanced 2021 notes in unsecured market Revenue growth in specialty waxes

28

Contact Information

CONTACT INFORMATION

Joe Caminiti or Chris Hodges

Alpha IR

312-445-2870

Email: [email protected]


Recommended